BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Revenue of BioAtla, Inc. (BCAB)
Revenue in 2023 (TTM): $
According to BioAtla, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of BioAtla, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-103,731,000 | $-122,241,000 | $-123,462,000 | $-123,462,000 |
| 2022 | $ | $-1,199,000 | $-106,482,000 | $-106,482,000 | $-105,283,000 |
| 2021 | $250 K | $-1,080,000 | $-94,069,000 | $-95,402,000 | $-95,406,000 |
| 2020 | $429 K | $409.07 K | $-33,456,000 | $-35,853,000 | $-37,241,000 |
| 2019 | $5.2 M | $5.17 M | $-27,365,000 | $-29,855,000 | $-31,402,000 |
| 2018 | $10.63 M | $-15,678,000 | $-27,236,000 | $-28,979,000 | $-28,979,000 |